Appendix 2—table 36. Antidiabetic Cohort (All Regions), Patient Characteristics Pre/Post Match.
| All Observations by Antidiabetic Use: Unmatched | All Observations by Antidiabetic Use: Matched | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All | DIAB Non-users | DIAB Users | p-value | All | DIAB Non-users | DIAB Users | p-value | |||||||
| N | % | N | % | N | % | N | % | N | % | N | % | |||
| All Patients | 7,906,603 | 100.0% | 7,151,351 | 90.4% | 755,252 | 9.6% | 1,509,106 | 100.0% | 754,553 | 50.0% | 754,553 | 50.0% | ||
| Age | ||||||||||||||
| ≤20 | 1,840,050 | 23.3% | 1,833,838 | 25.6% | 6,212 | 0.8% | <0.001 | 12,422 | 0.8% | 6,211 | 0.8% | 6,211 | 0.8% | 1.00 |
| 21-40 | 1,446,999 | 18.3% | 1,389,243 | 19.4% | 57,756 | 7.6% | 115,448 | 7.7% | 57,723 | 7.6% | 57,725 | 7.7% | ||
| 41-50 | 925,309 | 11.7% | 833,333 | 11.7% | 91,976 | 12.2% | 183,810 | 12.2% | 91,905 | 12.2% | 91,905 | 12.2% | ||
| 51-60 | 1,250,190 | 15.8% | 1,058,878 | 14.8% | 191,312 | 25.3% | 382,390 | 25.3% | 191,196 | 25.3% | 191,194 | 25.3% | ||
| 61-70 | 1,181,261 | 14.9% | 973,670 | 13.6% | 207,591 | 27.5% | 414,869 | 27.5% | 207,435 | 27.5% | 207,434 | 27.5% | ||
| 71-80 | 783,775 | 9.9% | 645,256 | 9.0% | 138,519 | 18.3% | 276,619 | 18.3% | 138,310 | 18.3% | 138,309 | 18.3% | ||
| ≥81 | 479,019 | 6.1% | 417,133 | 5.8% | 61,886 | 8.2% | 123,548 | 8.2% | 61,773 | 8.2% | 61,775 | 8.2% | ||
| Gender | ||||||||||||||
| Female | 4,670,960 | 59.1% | 4,212,086 | 58.9% | 458,874 | 60.8% | <0.001 | 916,914 | 60.8% | 458,455 | 60.8% | 458,459 | 60.8% | 0.99 |
| Male | 3,235,643 | 40.9% | 2,939,265 | 41.1% | 296,378 | 39.2% | 592,192 | 39.2% | 296,098 | 39.2% | 296,094 | 39.2% | ||
| Region | ||||||||||||||
| Midwest | 1,467,802 | 18.6% | 1,333,631 | 18.6% | 134,171 | 17.8% | <0.001 | 268,044 | 17.8% | 134,022 | 17.8% | 134,022 | 17.8% | 1.00 |
| Northeast | 2,152,560 | 27.2% | 1,935,311 | 27.1% | 217,249 | 28.8% | 434,080 | 28.8% | 217,040 | 28.8% | 217,040 | 28.8% | ||
| South | 3,042,604 | 38.5% | 2,752,618 | 38.5% | 289,986 | 38.4% | 579,562 | 38.4% | 289,781 | 38.4% | 289,781 | 38.4% | ||
| West | 1,243,637 | 15.7% | 1,129,791 | 15.8% | 113,846 | 15.1% | 227,420 | 15.1% | 113,710 | 15.1% | 113,710 | 15.1% | ||
| Insurance | ||||||||||||||
| Commercial | 3,938,603 | 49.8% | 3,631,514 | 50.8% | 307,089 | 40.7% | <0.001 | 614,045 | 40.7% | 307,022 | 40.7% | 307,023 | 40.7% | 1.00 |
| Dual | 156,497 | 2.0% | 113,496 | 1.6% | 43,001 | 5.7% | 85,209 | 5.6% | 42,603 | 5.6% | 42,606 | 5.6% | ||
| Medicaid | 2,594,500 | 32.8% | 2,387,519 | 33.4% | 206,981 | 27.4% | 413,743 | 27.4% | 206,875 | 27.4% | 206,868 | 27.4% | ||
| Medicare | 1,217,003 | 15.4% | 1,018,822 | 14.2% | 198,181 | 26.2% | 396,109 | 26.2% | 198,053 | 26.2% | 198,056 | 26.2% | ||
| PCP Visit 2019 | ||||||||||||||
| No | 4,283,697 | 54.2% | 4,030,804 | 56.4% | 252,893 | 33.5% | <0.001 | 505,500 | 33.5% | 252,752 | 33.5% | 252,748 | 33.5% | 0.99 |
| Yes | 3,622,906 | 45.8% | 3,120,547 | 43.6% | 502,359 | 66.5% | 1,003,606 | 66.5% | 501,801 | 66.5% | 501,805 | 66.5% | ||
| Continuous Outcomes | ||||||||||||||
| mean | SD | mean | SD | mean | SD | p-value | mean | SD | mean | SD | mean | SD | p-value | |
| CCI | 0.62 | 1.38 | 0.55 | 1.30 | 1.25 | 1.84 | <0.001 | 1.24 | 1.82 | 1.24 | 1.82 | 1.24 | 1.82 | 0.99 |
CCI: Charlson Comorbidity Index; DIAB: antidiabetic; PCP: primary care physician; SD: standard deviation.